Carcinoma ex pleomorphic adenoma: A review of incidence, demographics, risk factors, and survival

Am J Otolaryngol. 2019 Nov-Dec;40(6):102279. doi: 10.1016/j.amjoto.2019.102279. Epub 2019 Aug 21.

Abstract

Purpose: Identify variables that are independent predictors of survival in carcinoma ex pleomorphic adenoma (CXPA) of the major salivary glands using a population-based database and evaluate the incidence and management strategies for this rare malignancy.

Materials and methods: The Surveillance, Epidemiology, and End Results (SEER) database was queried for all cases of major salivary gland CXPA from 1973 to 2015.

Results: Of the 619 patients identified, the parotid gland was the most common site of involvement (76.9%, 476/619). The reported incidence of CXPA has risen in the past decade (2005-2015, 0.24 to 0.63 per 1,000,000). The 2-year and 5-year disease-specific survival (DSS) rates were 90.3% and 80.4%, respectively. On univariate analysis, facial nerve sacrifice was not a statistically significant predictor of survival (HR = 1.213, 95% CI [0.588-2.058], P = 0.602). Patients with a tumor size >4 cm, multiple positive lymph nodes, and distant metastatic disease had a 2 to 4-fold statistically significant increase in mortality using a multivariate analysis. Statistical significance was not demonstrated in the DSS of patients who underwent partial versus total parotidectomy procedures.

Conclusions: CXPA is a rare salivary malignancy that has a reported increased incidence in the last decade. Tumor size >4 cm, multiple positive lymph nodes, and distant metastatic disease are predictors of disease-specific mortality. Further research should be conducted to improve early detection and survival strategies for this salivary cancer.

Level of evidence: 4.

Keywords: Carcinoma ex pleomorphic adenoma; Parotid gland; Salivary malignancy; Survival.

MeSH terms

  • Adenoma, Pleomorphic / epidemiology*
  • Aged
  • Carcinoma / epidemiology*
  • Female
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Factors
  • SEER Program
  • Salivary Gland Neoplasms / epidemiology*
  • Socioeconomic Factors
  • Survival Rate